Pharmaresearch has a strong brand (Rejuran) but faced multiple compression due to competition from L&C Bio's new product. Improvement in its cosmetics division margins should drive a rebound in the stock.
AI capex is not declining, AI monetization has not failed, and the market is still mid-cycle despite oil and rate headwinds. Investors should focus on AI infrastructure including DRAM, nuclear power, and solar power.